Drug Profile


Alternative Names: Resolvine; Resolvine ER

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator KATO Pharmaceuticals
  • Developer KATO Pharmaceuticals; Ophthalmic Consultants of Boston
  • Class Anti-inflammatories; Eye disorder therapies; Omega 3 fatty acids
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Diabetic retinopathy
  • No development reported Retinal disorders

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for phase-I development in Retinal-disorders in USA (Intravitreous, Injection)
  • 10 Oct 2016 Kato Pharmaceuticals plans a phase II trial in Diabetic retinopathy in USA
  • 07 Oct 2016 Resolvine ER licensed to Lee's Pharmaceuticals in China, Hong Kong, Macau, Taiwan and South East Asia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top